RxDoctor Payments Data

John Davis, MD

Otolaryngology · Hoover, ALNPI 1124113501

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $159,473 of the $250,843 with a category attached, or 63.6%. 25 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 26.4% of the total. 2025 is the largest year on record at $83,085, more than ten times the $411 reported in 2019. Among otolaryngology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$250,843in general payments, 2019–2025

Across 420 payments — averaging $597.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$66K
  • Sanofi$55K
  • Aerin Medical Inc.$52K
  • GSK$47K
  • Intersect ENT, Inc.$12K
  • Spirair, Inc.$11K
  • plus $7K from 19 others
$139,655in research payments, 2019–2025

Across 97 payments — averaging $1439.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurent Medical Limited$46K
  • Aerin Medical Inc.$35K
  • Regeneron$35K
  • Sanofi US Services Inc.$24K

What the payments were for

  • Consulting fees$63,99526%
  • Speaking & faculty fees$159,47364%
  • Travel & lodging$16,3827%
  • Food & beverage$10,8944%
  • Education$980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$250,843 in reported general payments places this provider in the 95th percentile of 155 otolaryngology providers in Alabama.

See all otolaryngology providers in Alabama

Medicare billing

Part B allowed, 2024
$183,086
Medicare patients
275
Services billed
1,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab12$44,296
Dexlansoprazole DrDexlansoprazole35$9,779
Omeprazole136$1,878
Ipratropium Bromide60$1,745
Azelastine Hcl43$1,061
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav72$785
Esomeprazole Magnesium12$782
Pantoprazole Sodium47$733
Cefdinir29$683
Montelukast Sodium58$580
Ondansetron OdtOndansetron38$446
Ofloxacin11$444
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen30$391
Famotidine24$306
Prednisone76$269

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Hoover

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →